We have enjoyed meeting you at the 16th European ISPOR conference in Dublin, November 2013.
Journal of Medical Economics (September 2013) publishes Pharmerit´s cost-effectiveness study on adjuvant therapy to prevent gastrointestinal stromal tumour recurrence.
England and Wales’ National Institute for Health and Care Excellence (NICE) has positively
reviewed the pharmaco-economic submission by the manufacturer of ocriplasmin (Jetrea®).
Publication on alpha-blocker and anti-muscarinic combination treatment has been
positively reviewed by the NHS Centre for Reviews and Dissemination (CRD).
Pharmerit International staff participated as exhibitors at AMCP’s 25th Annual
Meeting & Expo held April 3-5th at the San Diego Convention Center in San Diego,
Biologic treatment in RA is associated with high acquisation costs. In addition, some biologics have been linked to antibody development which is associated with potentially detrimental impacts on effectiveness over time.
Pharmerit International is pleased to announce that our paper Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy is published in Pain Practice, issue 4, 2013.
Pharmerit International is pleased to report that its research was recently reported at the 2013 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), February 22 to 26, in San Antonio, TX.
Pharmerit International is proud to announce that its paper titled "Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes" has been recommended as being of special significance in its field.
The article, “Understanding and use of dynamic models in health economic analyses,” is published in Volume 18, Issue 6, of ISPOR CONNECTIONS and presents the basic principles for the use of dynamic modeling in a manner accessible to all researchers.